<Li> Signed into law by President William J. Clinton on November 21, 1997 </Li> <P> The United States Food and Drug Administration Modernization Act of 1997 (FDAMA) amended the Federal Food, Drug, and Cosmetic Act . This act is related to the regulation of food, drugs, devices, and biological products by the FDA . These changes were made in order to recognize the changes in the way the FDA would be operating in the 21st century . The main focus of this is the acknowledgment in the advancement of technological, trade, and public health complexities . </P> <P> Congressman Richard Burr and Senator James M. Jeffords were the chairperson sponsors of the Food and Drug Administration Regulatory Modernization Act of 1997 or Food and Drug Administration Modernization Act of 1997 . The U.S. legislation was signed by Bill Clinton on 21 November 1997, and was fully enacted by 1 April 1999, putting into law reforms begun under the National Partnership for Reinventing Government . One result of the passing of the act was a reduction in the time for the approval of new pharmaceutical drugs . </P> <P> The FDA Modernization Act of 1997 was a piece of legislation that concentrated on reforming the regulation of food, medical products, and cosmetics in the United States . The following are the most significant provisions of the act: </P>

In response to criticism related to the time lag for drug approval which act was passed in 1997